9.125
Schlusskurs vom Vortag:
$8.87
Offen:
$8.86
24-Stunden-Volumen:
187.18K
Relative Volume:
1.08
Marktkapitalisierung:
$304.96M
Einnahmen:
$56.13M
Nettoeinkommen (Verlust:
$-14.67M
KGV:
-12.33
EPS:
-0.74
Netto-Cashflow:
$-9.13M
1W Leistung:
+9.15%
1M Leistung:
+13.92%
6M Leistung:
+25.52%
1J Leistung:
+147.96%
Journey Medical Corp Stock (DERM) Company Profile
Firmenname
Journey Medical Corp
Sektor
Telefon
480-434-6670
Adresse
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Vergleichen Sie DERM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
DERM
Journey Medical Corp
|
9.17 | 294.99M | 56.13M | -14.67M | -9.13M | -0.74 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | ROTH MKM | Buy |
| 2021-12-07 | Eingeleitet | B. Riley Securities | Buy |
Journey Medical Corp Aktie (DERM) Neueste Nachrichten
Published on: 2026-01-20 22:55:08 - baoquankhu1.vn
Does Autonomix Medical Inc meet Warren Buffetts criteriaJuly 2025 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Journey Medical Corp: Small-Cap Dermatology Stock Walks a Tightrope Between Turnaround Hopes and Vol - AD HOC NEWS
Is Cerus Corporation being accumulated by smart money2025 Volume Leaders & High Accuracy Investment Signals - baoquankhu1.vn
Journey Medical Corporation (NASDAQ:DERM) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Given Average Recommendation of “Hold” by Analysts - Defense World
Journey Medical (NASDAQ:DERM) Trading 3.4% HigherHere's What Happened - MarketBeat
WebMD Launches Embody -- A Whole-Self Health, Weight Loss, and Weight Management Platform - The AI Journal
Early ZYCUBO treatment cut death risk nearly 80% in children with Menkes - Stock Titan
CVS Health Corp.: How a Pharmacy Giant Is Re?Engineering the Front Door to U.S. Healthcare - AD HOC NEWS
Axillary Hyperhidrosis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Botanix Pharma, Sound Surgical Tech, Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corp. - Barchart.com
Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data - MSN
Will Journey Medical Corporation stock gain from government policiesJuly 2025 Retail & AI Enhanced Trading Signals - Улправда
Is Microbot Medical Inc. (CY9D) stock vulnerable to rate hikesWeekly Stock Report & Weekly High Return Opportunities - ulpravda.ru
Can Tenon Medical Inc. Equity Warrant stock hit record highs againJuly 2025 Retail & Weekly Hot Stock Watchlists - Улправда
Why Orthofix Medical Inc. (OM2) stock is upgraded to buyAnalyst Upgrade & Safe Capital Growth Tips - Улправда
IMG Opens Applications for 2026 Spring Semester 'Student Journey Scholarship' - Yahoo Finance
Best Medical Travel Insurance Companies of 2026 - U.S. News & World Report
9 Best Performing Micro Cap Stocks in 2025 - Insider Monkey
10 Best Travel Insurance Companies For 2026 - Forbes
The Truth About Journey Medical Corp (DERM): Tiny Stock, Big Drama – Is It Worth the Hype? - AD HOC NEWS
Layoff Tracker: Nido Will Close Following Lead Candidate’s Disappointing Phase II Results - BioSpace
Fourteen new option listings on November 12th - MSN
Public companies account for 34% of Journey Medical Corporation's (NASDAQ:DERM) ownership, while institutions account for 33% - Yahoo Finance
Journey Medical Corporation (NASDAQ:DERM) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Earnings Beat: Why Profound Medical Corp stock attracts high net worth investorsMarket Trend Review & Risk Controlled Swing Trade Alerts - moha.gov.vn
Aug Weekly: Can Quipt Home Medical Corp. stock reach $100 price targetPortfolio Return Report & Reliable Entry Point Alerts - ulpravda.ru
Journey Medical (NASDAQ:DERM) Trading 2.1% Higher – What’s Next? - Defense World
How Orthofix Medical Inc. stock performs in interest rate cycles2025 Volatility Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
Sheets Smith Investment Management Invests $946,000 in Journey Medical Corporation $DERM - MarketBeat
Is Journey Medical Corporation stock cheap at current valuationWeekly Trade Review & Target Return Focused Stock Picks - Улправда
Journey Medical (NASDAQ:DERM) Trading 2.1% HigherWhat's Next? - MarketBeat
How Journey Medical Corporation stock benefits from tech adoptionWeekly Investment Summary & Smart Allocation Stock Tips - Улправда
Can Zhejiang Taimei Medical Technology Co. Ltd. (A2V) stock ride next bull market cycleMarket Sentiment Summary & Entry Point Confirmation Alerts - Улправда
Can Unidoc Health Corp. (L7T) stock beat analyst consensusJuly 2025 Patterns & Low Risk High Win Rate Stock Picks - Улправда
Is Journey Medical Corporation stock a buy on dipsEarnings Miss & Technical Analysis for Trade Confirmation - Улправда
How analysts rate Quipt Home Medical Corp. stock todayWeekly Gains Report & Accurate Trade Setup Notifications - Улправда
Fortress Biotech (Nasdaq: FBIO): FDA accepts Class 1 resubmission, CUTX-101 PDUFA Jan. 14, 2026 - Stock Titan
Journey Medical announces results from phase 1 trial of DFD-29 - MSN
Our Products | Full Products and Solutions List | Abbott U.S. - Abbott
Minocycline study shows no microbiome disruption after 16-week use By Investing.com - Investing.com Nigeria
Journey Medical announces results from Phase 1 trial of DFD-29 - TipRanks
DERM FinancialsIncome Statement - Quiver Quantitative
Minocycline study shows no microbiome disruption after 16-week use - Investing.com India
Journey Medical Corporation Reports Positive Phase 1 Trial Results for Emrosi, Meeting All Primary Objectives with No Safety Issues - Quiver Quantitative
Journey Medical (Nasdaq: DERM) posts Phase 1 Emrosi data on 16-week microbiome profile - Stock Titan
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - Yahoo Finance
Aleen Inc. Introduces Wellness AI: A Journey into Self-Discovery, Not Medical Diagnosis - TradingView — Track All Markets
DERM Stock On The Rise: Worth Watching As Emrosi Adoption Expands - RTTNews
Journey Medical (DERM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Price Action: Why Omega Healthcare Investors Inc. stock attracts high net worth investors2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Finanzdaten der Journey Medical Corp-Aktie (DERM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Journey Medical Corp-Aktie (DERM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Maraoui Claude | President & CEO |
May 02 '25 |
Sale |
6.84 |
4,834 |
33,065 |
2,348,313 |
| Benesch Joseph | CFO |
May 02 '25 |
Sale |
6.84 |
2,409 |
16,478 |
203,557 |
| Alloush Ramsey | COO |
May 02 '25 |
Sale |
6.84 |
2,857 |
19,542 |
504,817 |
| Maraoui Claude | President & CEO |
Mar 11 '25 |
Sale |
5.01 |
49,271 |
246,848 |
2,003,147 |
| Maraoui Claude | President & CEO |
Mar 06 '25 |
Sale |
5.04 |
25,551 |
128,777 |
2,067,323 |
| Maraoui Claude | President & CEO |
Mar 07 '25 |
Sale |
5.01 |
14,905 |
74,674 |
2,052,418 |
| Maraoui Claude | President & CEO |
Mar 04 '25 |
Sale |
5.04 |
28,901 |
145,661 |
2,111,021 |
| Maraoui Claude | President & CEO |
Mar 03 '25 |
Sale |
5.19 |
23,508 |
122,007 |
2,139,922 |
| Maraoui Claude | President & CEO |
Mar 05 '25 |
Sale |
5.13 |
18,147 |
93,094 |
2,092,874 |
| Benesch Joseph | CFO |
Feb 21 '25 |
Sale |
5.19 |
1,365 |
7,084 |
45,966 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):